Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chloride transport protein 6 (CLCN6, ClC-6) is an intracellular, predominantly neuronal, voltage-gated chloride/proton exchanger localized to late endosomes and lysosomes, where it mediates Cl^–/H^+ exchange essential for normal endolysosomal acidification and neuronal function[2][4]. Structurally, it is a dimeric protein with each monomer consisting of an 18-helix transmembrane domain and cytoplasmic cystathionine β-synthase (CBS) domains, and it exhibits complex voltage-dependent gating properties distinct from plasma-membrane CLC channels[2][3]. Loss-of-function or gain-of-function mutations in CLCN6 are established genetic causes of severe early-onset neurodegenerative disease, highlighting its essential role in the nervous system[2][3][4]. There are currently no known drugs that target ClC-6 directly in clinical use.
Not established for therapeutic drugs; native action is voltage-gated, pH-sensitive Cl^–/H^+ exchange (antiport) in endosomal compartments[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chloride transport protein 6 (CLCN6).